Soricimed Announces the Appointment of Dr. Marc Rubin and Mr. Vaughn Embro-Pantalony to Board of Directors
March 19 2018 - 2:30PM
Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage
pharmaceutical company discovering and developing targeted cancer
therapeutics, is pleased to announce that Marc Rubin, MD and Vaughn
Embro-Pantalony have been appointed to the Company’s Board of
Directors, effective immediately.
“We are pleased to welcome Marc and Vaughn to
the Board of Directors of Soricimed Biopharma Inc. Their
pharmaceutical and financial experience will help the company as we
move forward,” said Tom Reeves, Chairman of Soricimed. “We
believe the combination of domestic and global business experience
that they bring will be a significant asset to the Board.
They bring a wealth of industry knowledge to our Company and both
have strong track records as leaders in the Life Sciences
sector. We look forward to leveraging their expertise as we
move Soricimed forward.”
Dr. Rubin commented: “I am excited to join
Soricimed’s Board. This is a unique opportunity to help shape
a company with significant assets addressing a global unmet
need.”
“I am thrilled to be joining Soricimed’s Board
at this important time,” said Mr. Embro-Pantalony. “I look
forward to working with the Company as we move further through our
clinical development.”
Rick Pryde, a long-serving director of Soricimed
will be stepping down from the Board. “Rick joined us as a
board member when we were a young company,” said Jack Stewart,
Founder and CSO. “The experience and insight he brought to us
certainly helped shape our direction over the last years.
Many thanks, Rick”.
About the New Board Members
Dr. Rubin brings extensive global
pharmaceutical, biotech and financing experience to
Soricimed. Currently Marc is Executive Chairman of Titan
Pharmaceuticals, Inc. (NASDAQ:TTNP), after serving as its President
and CEO. Dr. Rubin’s pharmaceutical experience includes being
Head of Global Research and Development for Bayer Schering Pharma,
as well as senior positions with global research and development as
well as commercial responsibilities at GlaxoSmithKline. Dr.
Rubin holds an M.D. from Cornell University Medical College and is
board certified in internal medicine, medical oncology and
infectious diseases.
Mr. Embro-Pantalony brings extensive
pharmaceutical and biotech experience and a strong background in
finance and business development. Currently Vaughn is a board
member and former President and CEO of Microbix Biosystems Inc., a
Canadian public biotech company (TSX:MBX). Prior to this Mr.
Embro-Pantalony held V.P. Finance and CFO positions with Teva
Novopharm, Ltd. and Bayer Healthcare in Canada. Mr.
Embro-Pantalony holds an MBA from the University of Windsor and is
a Fellow Chartered Professional Accountant.
About Soricimed
Biopharma: Soricimed Biopharma Inc. is a private
Canadian clinical-stage company developing novel cancer
therapeutics and diagnostics. Soricimed’s drug candidates have
demonstrated a capability to reduce cancer cell viability, induce
apoptosis and to reduce human tumour volume while minimizing
side-effects in classic animal and in vitro tumour models.
Soricimed recently announced positive results indicating safety,
tolerability and potential activity in a Multi-centre Phase I trial
of SOR-C13 in subjects with advanced solid tumour cancers.
Additionally, Soricimed obtained two orphan drug statuses for
treatment of ovarian and for pancreatic cancers with SOR-C13.
Privately held, Soricimed is funded through private investors and
various programs from the Governments of Canada and New Brunswick.
For more information please visit, www.soricimed.com.
For More Information:Paul Gunn,
President & CEOSoricimed Biopharma Inc.pgunn@soricimed.com
506-866-0400
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Oct 2023 to Oct 2024